Published in Pharma Law Weekly, December 6th, 2011
The investigation concerns whether the board of directors are breaching their fiduciary duties by failing to adequately shop the Company and maximize shareholder value. Under the terms of the agreement, Pharmasset shareholders would receive $137 per share in a cash tender offer. However, the Company has three clinical-stage product candidates for the treatment of chronic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.